Qube Research & Technologies (QRT)
ANTX icon

Qube Research & Technologies (QRT)’s AN2 Therapeutics ANTX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$82.7K Buy
24,168
+13,984
+137% +$28.9K ﹤0.01% 3095
2025
Q4 		$11.6K Hold
10,184
– – ﹤0.01% 3440
2025
Q3 		$12.9K Hold
10,184
– – ﹤0.01% 3324
2025
Q2 		$10.8K Hold
10,184
– – ﹤0.01% 3311
2025
Q1 		$13.8K Sell
10,184
-1
-0% -$1 ﹤0.01% 3256
2024
Q4 		$14.1K Buy
+10,185
New +$12.4K ﹤0.01% 3213
2024
Q3 		– Sell
-10,186
Closed -$21.9K – 3267
2024
Q2 		$21.9K Sell
10,186
-40,179
-80% -$95.6K ﹤0.01% 2869
2024
Q1 		$164K Sell
50,365
-21,843
-30% -$238K ﹤0.01% 3118
2023
Q4 		$1.48M Buy
+72,208
New +$1.21M ﹤0.01% 1693
2023
Q3 		– Sell
-18,361
Closed -$156K – 4070
2023
Q2 		$156K Buy
+18,361
New +$132K ﹤0.01% 1854

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ANTX Position: Q1 2026 in Review

Qube Research & Technologies (QRT) increased its AN2 Therapeutics (ANTX) stake by 137% in Q1 2026, buying an estimated $28.9K and bringing the position to 24,168 shares worth $82.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3095.

Qube Research & Technologies (QRT) first reported a position in ANTX in Q2 2023 and has held it in 10 quarters since. The position peaked at $1.48M in Q4 2023. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Qube Research & Technologies (QRT) held 24,168 shares of AN2 Therapeutics worth $82.7K as of Q1 2026.
  • Qube Research & Technologies (QRT) bought 13,984 AN2 Therapeutics shares in Q1 2026, an estimated $28.9K.
  • AN2 Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #3095 holding.
  • Qube Research & Technologies (QRT) first reported a position in AN2 Therapeutics in Q2 2023 and has held it in 10 quarters since.
  • Qube Research & Technologies (QRT)'s AN2 Therapeutics position peaked at $1.48M in Q4 2023.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.